AstraZeneca may be about to reverse its plans for fresh investment in Macclesfield – building a drug production plant in Ireland instead – after a dispute with the Government.
The row is thought to have been triggered by the decision to order booster Covid jabs from rival, Pfizer.
According to some reports, Chief executive Pascal Soriot ‘threw his toys out of the pram’ after the decision.
Ministers were offering up to £55 million of subsidies for A-Z for the Macclesfield project before the rift.
It’s being stated that Soriot was so incensed by the booster vaccine snub he reverted to his original plan to build a manufacturing plant in Ireland, which offers more favourable tax breaks.
However, the decision could be reversed. A-Z previously spent £ millions attempting to move production of its highly successful Nolvadex anti-cancer drug overseas – but consistently failed to achieve the extremely high standards of the Macclesfield plant.
In May construction began in Macclesfield on a sterile production plant for a cancer drug, which is used to treat patients with prostate, breast and gynaecological disorders.
Work is set to be completed by the end of next year.
A-Z teamed up with Oxford University to create the Covid jabs, and began work on a booster vaccine over the summer. But its jab was focused on the Beta variant, which first emerged in South Africa, which has been less prevalent in recent months, as Delta has taken hold.
The company is not selling its Covid vaccine at a profit, an unprecedented move by a multinational business. This prompted the World Health Organisation to hail the jab as a ‘vaccine for the world’.
Critics in the EU have rounded on A-Z over supply chain problems and blamed it for the bloc’s handling of the vaccination programme.
This website uses cookies to improve the experience our website users receive and to track page hits and the like. If you continue to use our website then we are assuming you're ok with this, but you can opt-out if you wish.AcceptRead More
I ❤ Macc Cookie Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
You must be logged in to post a comment Login